Treventis Corporation
Treventis Corporation is dedicated to treating and preventing protein misfolding diseases using its proprietary, patented discovery engine – Common Conformational Morphology (CCM). The company focuses on drug discovery for neurodegenerative diseases such as Alzheimer’s, tauopathies, ALS, Parkinson’s, and cancer, leveraging its innovative technology platform to identify druggable active sites in misfolded proteins.
Industries
Nr. of Employees
small (1-50)
Treventis Corporation
Products
Small-molecule tau and Aβ oligomer inhibitor program (Alzheimer’s and tauopathies)
Preclinical program to discover and optimize small molecules that inhibit tau and Aβ oligomerization using in silico modeling followed by in vitro and in vivo validation; advanced compounds have demonstrated oral bioavailability and in vivo target engagement.
Broad-spectrum TDP oligomer inhibitor program (ALS and TDP-mediated FTD)
Discovery program focused on small molecules that inhibit misfolding/oligomerization of TDP isoforms with the goal of halting aggregate growth and disease progression; multiple chemotypes identified with activity in turbidity and cell-based assays.
p53 oligomer inhibitor program (oncology)
Preclinical discovery of small molecules that inhibit aggregation/oligomerization of mutant p53 with the aim of restoring tumor suppressor function or preventing toxic gain-of-function; initial hits show dose-dependent inhibition and selective activity in mutant p53 cell models.
Small-molecule tau and Aβ oligomer inhibitor program (Alzheimer’s and tauopathies)
Preclinical program to discover and optimize small molecules that inhibit tau and Aβ oligomerization using in silico modeling followed by in vitro and in vivo validation; advanced compounds have demonstrated oral bioavailability and in vivo target engagement.
Broad-spectrum TDP oligomer inhibitor program (ALS and TDP-mediated FTD)
Discovery program focused on small molecules that inhibit misfolding/oligomerization of TDP isoforms with the goal of halting aggregate growth and disease progression; multiple chemotypes identified with activity in turbidity and cell-based assays.
p53 oligomer inhibitor program (oncology)
Preclinical discovery of small molecules that inhibit aggregation/oligomerization of mutant p53 with the aim of restoring tumor suppressor function or preventing toxic gain-of-function; initial hits show dose-dependent inhibition and selective activity in mutant p53 cell models.
Services
Collaborative discovery partnerships and licensing
Collaborative research, option/license arrangements and partnership-based advancement of preclinical small-molecule programs using an in silico-driven discovery platform; engagement with pharmaceutical partners and government-funded research awards.
Collaborative discovery partnerships and licensing
Collaborative research, option/license arrangements and partnership-based advancement of preclinical small-molecule programs using an in silico-driven discovery platform; engagement with pharmaceutical partners and government-funded research awards.
Expertise Areas
- Protein misfolding drug discovery
- Small-molecule oligomerization inhibitors
- Neurodegenerative disease preclinical development (Alzheimer’s, ALS, Parkinson’s)
- Oncology-focused small-molecule discovery (mutant p53 aggregation)
Key Technologies
- In silico conformational modeling of misfolded proteins
- Virtual screening and structure-based drug design
- Medicinal chemistry and compound library synthesis
- Surface plasmon resonance (SPR)